TickerFacts.

Kairos Pharma, Ltd. (KAPA): R&D Expense

Annual figures by period end, from SEC filings.

$2.13M
Year ended 2025-12-31
$2.45M
Trailing 12 months to 2026-06-30
2023-12-31: $82.0K2024-12-31: $414.0K2025-12-31: $2.13M$2.13M
2023-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$2.13M+415.7%2026-03-31, From 2025-01-01
2024-12-31$414.0K+404.9%2026-03-31, From 2024-01-01
2023-12-31$82.0Kn/a2025-04-15, From 2023-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Kairos Pharma, Ltd. (KAPA)2025-12-31$2.13M+415.7%
Vyome Holdings, Inc (HIND)2025-12-31$588.3K+106.1%
Adial Pharmaceuticals, Inc. (ADIL)2025-12-31$2.62M-18.9%
GeoVax Labs, Inc. (GOVX)2025-12-31$18.12M-23.6%
OS Therapies Inc (OSTX)2025-12-31$16.36M+476.3%
Greenwich LifeSciences, Inc. (GLSI)2025-12-31$17.22M+11.2%
Serina Therapeutics, Inc. (SER)2025-12-31$13.15M+75.9%
CV Sciences, Inc. (CVSI)2025-12-31$122.0K+3.4%
Matinas BioPharma Holdings, Inc. (MTNB)2025-12-31$85.0K-99.3%

Compare KAPA, HIND, ADIL, GOVX side by side · Screen every company in Pharmaceutical Preparations ↗